Home > Journals > Minerva Stomatologica > Past Issues > Articles online first > Minerva Stomatologica 2020 Aug 03

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Stomatologica 2020 Aug 03

DOI: 10.23736/S0026-4970.20.04356-3

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Recognition of lysyl oxidase as a potential predictive biomarker for oral squamous cell carcinoma: an immunohistochemical study

Udhay BHANU, Srikant NATARAJAN, Nidhi MANAKTALA, Karen BOAZ , Rasika JOSHI, Sriranjani DEEPAK, Nandita KP, Amitha J. LEWIS

Department of Oral Pathology and Microbiology, Manipal College of Dental Sciences, Mangalore, Manipal Academy of Higher Education, Karnataka, India


PDF


BACKGROUND: Lysyl Oxidase (LOX) is a copper amine oxidase which belongs to the LOX multigene family and is normally involved in cross-linking of stromal collagen fibres. LOX expression has been found to be associated with increased episodes of recurrence, metastasis and overall poor prognosis in renal cell carcinomas and melanomas. This study aimed to assess the effects of LOX on the prognosis of Oral Squamous Cell Carcinoma (OSCC), which is one of the most common cancers in India.
METHODS: The immunohistochemical expression of Lysyl Oxidase using LOX2 primary antibody was assessed at the tumour proper, invasive tumour front and peri-tumoural stroma in tissue sections from 40 cases of histologically proven OSCC.
RESULTS: LOX expression was elevated in OSCC patients who had lymph node metastasis and in those who died of disease. No significant variation was seen with histological grade.
CONCLUSIONS: LOX has a ‘pro-neoplastic’ effect as it modulates the host stroma to favour increasing tumour mass and worsening prognosis. Increased expression of LOX causes increased collagen fibre cross-linkage that ‘stiffens’ the stromal matrix. This increases compressive stresses contributing to tissue hypoxia that elevates Rho GTPase-dependent cytoskeletal tension leading to erratic tumour cell morphogenesis that in turn confers motility to these cells resulting in metastasis. Inhibitors of LOX can potentially down-regulate LOX levels in the tumour micro-environment by controlling tissue hypoxia and curtailing the production of hypoxic LOX molecules.


KEY WORDS: Oral cancer; Lysyl oxidase; Hypoxia; Prognosis; Immunohistochemistry

top of page